Affimed Presents Data on AFM13-mediated Innate/Adaptive

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Affimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 2016

HEIDELBERG, Germany, April 21, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD ), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation of preclinical data from a combination study of Affimed's lead candidate AFM13 and checkpoint modulators at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New Orleans, LA.

In a poster presented on Monday, April 18, 2016, the Company, together with its collaboration partner Stanford University, provided further evidence for a synergy between its CD30/CD16A-specific NK-cell engager AFM13 and an anti-PD-1 antibody, shedding light on the molecular mechanisms underlying AFM13's previously reported tumor cell-killing properties.

Affimed expects to initiate a Phase 1b combination clinical trial this quarter and the Company's investigational new drug (IND) application for AFM13 in combination with pembrolizumab has recently been accepted by the U.S. Food and Drug Administration (FDA) and is now active. In the Phase1b study, Affimed will investigate AFM13 in combination with Merck's KEYTRUDA® for treatment of HL patients relapsed or refractory to chemotherapy, including Adcetris™. The trial is designed to assess safety and efficacy and to establish an optimal dosing regimen for the combination therapy.

"Combination therapy with checkpoint modulators is emerging as one of the most promising approaches in cancer immunotherapy and activating both components of the immune system, innate and adaptive immunity, is a major advantage," said Dr. Jens-Peter Marschner, CMO of Affimed. "We have shown that the combination of our NK-cell engager AFM13 with an anti-PD-1 antibody had this effect in the PDX model and we are now looking forward to developing this encouraging combination in the clinic with the intention to provide an effective but safe treatment to patients that have no further treatment options."

Data from in vivo PDX models with human CD30+ Hodgkin lymphoma (HL) tumors and immune cells derived from the patients' own PBMCs corroborated the previously described enhancement of AFM13 tumor cell lysis through combination with checkpoint modulators. The effect was most prominent for AFM13 in combination with anti PD-1. Tumor size, tumor-infiltrating human lymphocytes, myeloid cells and intratumoral cytokines were evaluated 2, 16 and 30 days after initiation of treatment. When both AFM13 and PD-1 were combined, a strong correlation between inhibition of tumor growth and increasing levels of tumor-infiltrating NK-cells, T-cells, myeloid cells and intratumoral cytokines such as IFNγ were observed, indicating a crosstalk between the innate and adaptive immune system. Over the course of the 30-day treatment period, the initial immune response is characterized by infiltration and activation of NK-cells and macrophages driven by AFM13 followed by the adaptive immune response via T-cells and activated dendritic cells driven by the combination.

The data presented at AACR strongly indicate that AFM13-mediated tumor infiltration and activation of different immune cell subpopulations is the molecular basis for the higher efficacy observed for AFM13 in combination with anti-PD-1 treatment.

About Affimed N.V.

Affimed (Nasdaq: AFMD ) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com .

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, collaborations, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in Affimed's filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

IR Contact:  Caroline Stewart, Head IR Phone: +1 347394 6793 E-Mail: IR@affimed.com or c.stewart@affimed.com

Media Contact:  Anca Alexandru, Head of Communications Phone: +49 6221 64793341 E-Mail: a.alexandru@affimed.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 222

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 64

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 202

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 86

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 41

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 177

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 94

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Labcorp's Brazil Trial Push Has Promise and Plenty to Prove

Updated Category News Views 93

Brazilian clinical-trial kit deliveries may soon spend less time tangled in international shipping. That is the practical heart of Labcorp's newly announced collaboration with Grupo Fleury, and frankly, practical is plenty good in this business. Labcorp plans to begin assembling clinical-trial kits locally in Brazil in early 2027, then add laboratory operations by the end...

Continue Reading

Top 5 Most Recently Viewed Articles

Hormel Foods Welcomes Debbra Schoneman to Board of Directors

Updated Category News Views 77

Debbra Schoneman Joins Hormel Foods Board of Directors Hormel Foods Corporation (NYSE: HRL), a leader in the global branded food sector, is excited to announce the election of Debbra Schoneman to its Board of Directors. This pivotal decision aligns with the company's ongoing dedication to excellence and innovative leadership. Debbra Schoneman's Background Jim Snee, the...

Continue Reading
Superorganism Secures $25.9M for Biodiversity Ventures

Updated Category News Views 182

Superorganism Secures $25.9M for Biodiversity Ventures Nature and technology fund backed by leading investors aims to redefine how capital advances biodiversity Superorganism, a pioneering venture capital firm focusing on technology solutions for biodiversity, recently announced the successful closure of its debut fund, garnering commitments amounting to $25.9 million....

Continue Reading
Teamsters Local 838 Welcomes First Student Workers in Missouri

Updated Category News Views 174

Teamsters Local 838 Welcomes First Student Workers In a significant development for school transportation workers, more than 100 bus drivers and monitors at First Student in Missouri have united under Teamsters Local 838. This successful vote marks a substantial step in expanding Teamster representation within the school transportation sector, ensuring these workers have...

Continue Reading
Exploring Promising Tech Innovators: Beyond the Giants

Updated Category News Views 121

Understanding the Tech Landscape The technology sector has captured the spotlight as one of the leading areas of growth in recent times. Yet, within this vast landscape, not all players enjoy the same level of success. Many people automatically think of established giants when they hear "tech"—companies often dubbed as the Magnificent Seven, including major players such...

Continue Reading
Highland Copper Innovates with New Drilling and Flotation Tech

Updated Category News Views 112

Highland Copper's New Drilling Program for Metallurgy Highland Copper Company Inc. is taking an exciting step forward with a new drilling program aimed at exploring and optimizing its mining operations. This initiative demonstrates Highland Copper's dedication to utilizing innovative and sustainable mining methods, significantly enhancing its project economics. Focusing...

Continue Reading